Business Context and Reporting Period
Company: Teleflex Incorporated (TFX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2026
Subject: Updates on two previously announced divestiture transactions: the sale of the Original Equipment and Manufacturing and Development Services business and the sale of the Acute Care and Interventional Urology business.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. Consequently, no data is provided for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Transaction Status
- Original Equipment and Manufacturing (OEM) Transaction:
- Buyer: Lotus US Bidco Inc. (affiliate of Montagu Private Equity LLP and Kohlberg & CO., L.L.C.).
- Status: The Hart-Scott-Rodino (HSR) Act waiting period expired on March 13, 2026, satisfying a key condition.
- Timeline: Anticipated to close in the third quarter of 2026.
- Conditions: Remains subject to other regulatory approvals and customary closing conditions.
- Acute Care and Interventional Urology Transaction:
- Buyer: Intersurgical Limited.
- Status: On March 11, 2026, both parties received a "Second Request" for additional information from the U.S. Federal Trade Commission (FTC).
- Impact: The HSR waiting period is extended until 30 days after substantial compliance with the Second Request.
- Timeline: Anticipated to close in the second half of 2026.
- Conditions: Remains subject to regulatory approvals and customary closing conditions.
- Independence: The two transactions are separate and may be consummated independently.
Guidance, Outlook, and Risks
Management Commentary: The Company states it is working cooperatively with the FTC regarding the Second Request for the Acute Care and Urology transaction.
Risks and Contingencies:
- Closing of both transactions remains subject to regulatory approvals and other conditions precedent.
- The Acute Care and Urology transaction faces an indefinite delay due to the FTC Second Request, pushing the anticipated closing to the second half of 2026.
Investor Verification Checklist
- Monitor the status of the FTC Second Request for the Acute Care and Urology transaction to assess potential further delays.
- Verify the specific "other regulatory approvals" required for the OEM transaction to close in Q3 2026.
- Review future filings for updates on the final closing dates and any changes to the transaction structure.
- Confirm the financial impact of these divestitures on future quarterly results once the transactions close.